['rheumatoid arthritis']
['placebo', 'upadacitinib']

        Inclusion Criteria:

          -  Adult male or female, at least 18 years old.

          -  Diagnosis of Rheumatoid Arthritis (RA) for greater than or equal to 3 months.

          -  Subjects have been receiving conventional synthetic DMARD (csDMARD) therapy for
             greater than or equal to 3 months and on a stable dose for greater than or equal to 4
             weeks prior to the first dose of study drug. The following csDMARDs are allowed:
             Methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.

          -  Meets the following minimum disease activity criteria: greater than or equal to 6
             swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  Subjects with prior exposure to at most one biologic DMARD (bDMARD) may be enrolled
             (up to 20% of study population) if they have documented evidence of intolerance to
             bDMARDs or limited exposure (less than 3 months) and have satisfied required washout
             periods.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  History of inflammatory joint disease other than RA. History of secondary Sjogren's
             Syndrome is permitted.

          -  Subjects who are considered inadequate responders to bDMARD therapy as determined by
             the Investigator.
      